Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ANNX

Annexon Inc

Nov 30 • 04:00PM ET

2.49

Dollar change -0.11
Percentage change -4.23	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.90	Insider Own	27.39%	Shs Outstand	47.72M	Perf Week	-0.80%
Market Cap	132.57M	Forward P/E	-	EPS next Y	-1.83	Insider Trans	2.10%	Shs Float	38.66M	Perf Month	9.69%
Income	-140.73M	PEG	-	EPS next Q	-0.48	Inst Own	73.87%	Short Float / Ratio	5.55% / 6.00	Perf Quarter	-9.45%
Sales	0.00M	P/S	-	EPS this Y	26.74%	Inst Trans	19.61%	Short Interest	2.15M	Perf Half Y	-17.00%
Book/sh	2.95	P/B	0.85	EPS next Y	3.74%	ROA	-54.49%	Target Price	9.00	Perf Year	-55.26%
Cash/sh	3.10	P/C	0.80	EPS next 5Y	38.60%	ROE	-67.42%	52W Range	1.57 - 7.65	Perf YTD	-51.84%
Dividend	-	P/FCF	-	EPS past 5Y	-39.49%	ROI	-75.40%	52W High	-67.45%	Beta	0.77
Dividend %	-	Quick Ratio	9.85	Sales past 5Y	0.00%	Gross Margin	-	52W Low	58.60%	ATR	0.22
Employees	80	Current Ratio	9.85	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	53.55	Volatility	9.51% 9.72%
Optionable	Yes	Debt/Eq	0.20	EPS Q/Q	15.57%	Profit Margin	-	Rel Volume	2.05	Prev Close	2.60
Shortable	Yes	LT Debt/Eq	0.19	Earnings	Nov 13 BMO	Payout	-	Avg Volume	357.60K	Price	2.49
Recom	1.44	SMA20	2.05%	SMA50	12.66%	SMA200	-29.62%	Volume	732,497	Change	-4.23%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Nov-22-23 04:01PM	Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 07:20PM	Annexon Inc (ANNX) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com) +9.73%
Nov-13-23 06:30AM	Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results (GlobeNewswire) +6.35%
Nov-09-23 06:30AM	Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-23 06:30AM	Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy (GlobeNewswire) +8.33%
04:01PM	Loading…
Oct-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-10-23 06:30AM	Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS) (GlobeNewswire)
06:30AM	Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Sep-19-23 06:30AM	Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-23 09:35AM	Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX) (Zacks)
Aug-07-23 06:30AM	Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-02-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-23 12:00PM	Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy (GlobeNewswire)
Jul-27-23 06:30AM	Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.82%
06:30AM	Loading…
Jul-24-23 06:30AM	Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023 (GlobeNewswire)
Jun-14-23 08:36AM	Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation (Simply Wall St.) -5.48%
May-30-23 10:40AM	Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why (Zacks)
May-26-23 03:05AM	4 big analyst cuts: Snowflake downgraded twice on guidance miss (Investing.com) +35.71%
May-25-23 11:52AM	Why Shares of Annexon Are Plummeting Thursday (Motley Fool) -59.38%
10:12AM	Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study (Benzinga)
May-24-23 04:01PM	Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function (GlobeNewswire) -7.84%
May-16-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-08-23 04:01PM	Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Apr-11-23 06:30AM	Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +5.95%
Mar-25-23 08:04AM	One Annexon, Inc. (NASDAQ:ANNX) insider upped their stake by 59% in the previous year (Simply Wall St.)
Mar-06-23 06:30AM	Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire) -6.77%
Feb-27-23 06:30AM	Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-16-23 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-23 07:35AM	Annexon, Inc.'s (NASDAQ:ANNX) Intrinsic Value Is Potentially 27% Above Its Share Price (Simply Wall St.)
04:30PM	Loading…
Jan-17-23 04:30PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-23 09:00AM	Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises (GlobeNewswire)
Jan-06-23 06:30AM	Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio (GlobeNewswire) +5.29%
Jan-04-23 06:30AM	Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-01-22 09:55AM	Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet (Zacks)
Nov-21-22 06:13AM	We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate (Simply Wall St.)
Nov-17-22 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-15-22 09:55AM	How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246% (Zacks)
Nov-03-22 06:30AM	Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023 (GlobeNewswire)
Oct-18-22 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-11-22 07:01AM	A Annexon, Inc. (NASDAQ:ANNX) insider increased their holdings by 59% last year (Simply Wall St.)
Sep-16-22 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-22 05:56PM	Amid Huntington's disease hopes and failures, Annexon targets new approach (American City Business Journals)
Aug-17-22 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-22 04:01PM	Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-11-22 06:25PM	Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025 (GlobeNewswire) -13.88%
Jul-08-22 07:00AM	Annexon Announces $130 Million Private Placement Financing (GlobeNewswire) +14.36%
Jun-07-22 12:19PM	Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues (Benzinga) +24.92%
06:30AM	Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntingtons Disease (GlobeNewswire)
Jun-02-22 06:30AM	Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-22 07:30AM	Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings (GlobeNewswire) -5.10%
May-09-22 04:01PM	Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 06:30AM	Annexon Biosciences to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-21-22 06:02AM	Insider Buying: The Annexon, Inc. (NASDAQ:ANNX) CEO, President & Director Just Bought 59% More Shares (Simply Wall St.) -5.86%
Apr-18-22 10:35AM	Is Annexon (NASDAQ:ANNX) In A Good Position To Invest In Growth? (Simply Wall St.)
Apr-07-22 06:30AM	Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy (GlobeNewswire) -5.34%
Apr-04-22 06:30AM	Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire) +15.41%
Mar-03-22 04:01PM	Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntingtons Disease at AAN 2022 (GlobeNewswire)
Mar-01-22 04:01PM	Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-28-22 06:30AM	Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference (GlobeNewswire) -5.54%
Jan-20-22 06:30AM	Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors (GlobeNewswire)
Jan-05-22 05:10PM	Why Annexon Biosciences Stock Plummeted 34% Today (Motley Fool) -34.06%
06:33AM	Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer (Benzinga)
Jan-04-22 04:05PM	Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntingtons Disease Following Six-Month Treatment (GlobeNewswire) -7.79%
06:30AM	Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-21 08:30AM	Do Options Traders Know Something About Annexon (ANNX) Stock We Don't? (Zacks)
Dec-13-21 09:00AM	Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition (GlobeNewswire) -6.15%
Nov-30-21 05:24AM	10 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Greens Redmile Group (Insider Monkey) +15.12%
Nov-28-21 11:17AM	3 Strong Buy Stocks for Bottom-Fishing Investors (TipRanks)
Nov-09-21 04:01PM	Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-19-21 06:38AM	We're Not Very Worried About Annexon's (NASDAQ:ANNX) Cash Burn Rate (Simply Wall St.)
Oct-04-21 10:49AM	Annexon, Inc. (ANNX): Hedge Fund Sentiment Unchanged (Insider Monkey)
06:30AM	Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Sep-23-21 06:30AM	Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-20-21 06:30AM	Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event (GlobeNewswire)
Sep-16-21 11:30AM	EVP And Chief Scientific Officer Of Annexon Trades $351.08 Thousand In Company Stock (Benzinga)
Aug-16-21 04:01PM	Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update (GlobeNewswire)
Jul-22-21 07:00AM	Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases (GlobeNewswire)
May-21-21 06:30AM	Moving Average Crossover Alert: Annexon (ANNX) (Zacks)
May-17-21 04:05PM	Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results (GlobeNewswire)
May-05-21 07:00AM	Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference (GlobeNewswire)
Apr-22-21 01:47AM	Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-25-21 07:00AM	Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights (GlobeNewswire)
Mar-01-21 01:11PM	Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy (Benzinga)
07:00AM	Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy (GlobeNewswire)
Feb-08-21 07:00AM	Annexon Welcomes William H. Carson, M.D. to the Board of Directors (GlobeNewswire) +8.18%
Jan-12-21 07:00AM	Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics (GlobeNewswire)
Jan-05-21 07:00AM	Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference (GlobeNewswire) -5.52%
Dec-21-20 07:00AM	Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome (GlobeNewswire) -9.21%
Dec-11-20 01:15PM	Is ANNX A Good Stock To Buy Now? (Insider Monkey)
Nov-16-20 04:01PM	Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-12-20 04:05PM	Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntingtons Disease Clinical Program (GlobeNewswire)
Oct-24-20 10:13AM	We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely (Simply Wall St.)
Sep-08-20 04:01PM	Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights (GlobeNewswire)
Jul-30-20 08:00AM	Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer (GlobeNewswire)
Jul-28-20 04:05PM	Annexon Announces Closing of Initial Public Offering (GlobeNewswire)

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bain Capital Life Sciences Inv	10% Owner	May 25	Buy	2.13	300,000	639,720	5,701,926	May 30 09:54 PM
Love Douglas	President & CEO	Feb 15	Sale	5.87	6,571	38,564	197,646	Feb 17 05:12 PM
Lew Jennifer	EVP & Chief Financial Officer	Feb 14	Sale	6.30	166	1,046	29,542	Feb 15 06:59 PM
Overdorf Michael	EVP & Chief Business Officer	Feb 14	Sale	6.30	144	907	27,805	Feb 15 07:00 PM
Lew Jennifer	EVP & Chief Financial Officer	Feb 13	Sale	6.31	1,742	10,989	29,708	Feb 15 06:59 PM
Overdorf Michael	EVP & Chief Business Officer	Feb 13	Sale	6.30	1,501	9,461	27,949	Feb 15 07:00 PM
Satter Muneer A	Director	Feb 10	Buy	6.80	2,647,058	17,999,994	7,056,024	Feb 14 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANNX

Annexon Inc

Upgrade your FINVIZ experience